Reinforcing, subjective, and physiological effects of MDMA in humans: A comparison with d-amphetamine and mCPP

Drug and Alcohol Dependence

Volumn 72, Issue 1, 2003, Pages 33-44

  Tancer, Manuel ^a   Johanson, Chris Ellyn ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Abuse liability; d Amphetamine; Dopamine; Humans; mCPP; MDMA; Reinforcing effects; Serotonin; Subjective effects

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; PIPERAZINE DERIVATIVE; PLACEBO; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN AGONIST;

ADDICTION; ADOLESCENT; ADULT; AFFECT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; REINFORCEMENT; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ANIMALIA;

EID: 0141918812     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00172-8     Document Type: Article

References (51)

1. Beardsley P.M., Balster R.L., Harris L.S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend. 18:1986;149-157.
2. Benkelfat C., Murphy D.L., Hill J.L., George D.T., Nutt D., Linnoila M. Ethanol-like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch. Gen. Psychiat. 48:1991;383.
3. Brauer L.H., Johanson C.E., Schuster C.R., Rothman R.B., de Wit H. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology. 14:1996;233-241.
4. Buydens-Branchey L., Branchey M., Fergeson P., Hudson J., McKernin C. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol. Psychiat. 41:1997;1071-1086.
5. Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., San L., de la Torre R. Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'): psychomotor performance and subjective effects. J. Clin. Psychopharm. 20:2000;455-466.
6. Chait L.D., Uhlenhuth E.H., Johanson C.E. The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology. 89:1986;301-306.
7. Chait L.D., Uhlenhuth E.H., Johanson C.E. The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol, and d-amphetamine in humans. Pharmacol. Biochem. Behav. 24:1986;1665-1672.
8. Chait L.D., Uhlenhuth E.H., Johanson C.E. Reinforcing and subjective effects of several anorectics in normal human volunteers. J. Pharmacol. Exp. Therap. 242:1987;777-783.
9. Croft R.J., Klugman A., Baldeweg T., Gruzelier J.H. Electrophysiological evidence of serotonergic impairment in long-term MDMA ('ecstasy') users. Am. J. Psychiat. 158:2001;1687-1692.
10. Curran H.V., Travill R.A. Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA,' ecstasy'): week-end 'high' followed by mid-week low. Addiction. 92:1997;821-831.
11. Dafters R.I., Duffy F., O'Donnell P.J., Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology. 145:1999;82-90.
12. de Wit H., Johanson C.E. A drug preference procedure for use with human volunteers. Bozarth M.A. Methods of Assessing the Reinforcing Properties of Abused Drugs. 1987;559-572 Springer, New York.
13. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology. 161:2002;356-364.
14. M.W. Fischman, Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs, in: M.W. Fischman, N.K. Mello (Eds.), Testing for the Abuse Liability of Drugs in Humans (NIDA Research Monograph). DHHS Publication No. (ADM) 89-1613, 1989, pp. 211-230.
15. Gouzoulis-Mayfrank E., Thelen B., Habermeyer E., Kunert H.J., Kovar K.A., Lindenblatt H., Hermle L., Spitzer M., Sass H. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology. 142:1999;41-50.
16. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J., Fimm B., Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol. Neurosurg. Psychiat. 68:2000;719-725.
17. Griffiths R.R., Troisi J.R., Silverman K., Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 4:1993;3-13.
18. R.R. Griffiths, G.E. Bigelow, N.A. Ator, 2003. Principles of initial experimental drug abuse liability assessment in humans. Drug and Alcohol Depend., 70, 541-554.
19. Grob C.S., Poland R.E., Chang L., Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav. Brain Res. 73:1996;103-107.
20. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Therap. 300:2002;1093-1100.
21. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 162:2002;396-405.
22. Johanson C.E., Uhlenhuth E.H. Drug preference and mood in humans: d-amphetamine. Psychopharmacology. 71:1980;275-279.
23. Jones H.E., Garrett B.E., Griffiths R.R. Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J. Pharmacol. Exp. Therap. 288:1999;188-197.
24. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiat. 30:1992;1139-1166.
25. Kalant H. The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. Can. Med. Assoc. J. 165:2001;917-928.
26. Lamb R.J., Griffiths R.R. Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology. 91:1987;268-272.
27. Lester S.J., Baggott M., Welm S., Schiller N.B., Jones R.T., Foster E., Mendelson J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Int. Med. 133:2000;969-973.
28. Liechti M.E., Baumann C., Gamma A., Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 22:2000;513-521.
29. Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology. 154:2001;161-168.
30. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective and behavioral effects of amphetamine, ephedrine, phemetrazine, and methylphenidate in man. Clin. Pharmacol. Therap. 12:1971;245-258.
31. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Therap. 290:1999;136-145.
32. McCann U.D., Eligulashvili V., Mertl M., Murphy D.L., Ricaurte G.A. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology. 147:1999;56-65.
33. McCann U.D., Eligulashvili V., Ricaurte G.A. 3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology. 42:2000;11-16.
34. D.M. McNair, M. Lorr, L.F. Droppleman, Manual for the profile of mood states. Educational and Industrial Testing Service, Educational and Industrial Testing Service, 1971.
35. Mumford G.K., Rush C.R., Griffiths R.R. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J. Pharmacol. Exp. Therap. 272:1995;570-580.
36. Obrocki J., Schmoldt A., Buchert R., Andresen B., Petersen K., Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol. Lett. 127:2002;285-297.
37. Parrott A.C. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology. 42:2000;17-24.
38. Pentney A.R. An exploration of the history and controversies surrounding MDMA and MDA. J. Psychoactive Drugs. 33:2001;213-221.
39. Peroutka S.J., Newman H., Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1:1988;273-277.
40. Pham J.V., Puzantian T. Ecstasy: dangers and controversies. Pharmacotherapy. 21:2001;1561-1565.
41. Ricaurte G.A., McCann U.D., Szabo Z., Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol. Lett. 112-113:2000;143-146.
42. Schuh L.M., Schuster C.R., Hopper J.A., Mendel C.M. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology. 147:2000;339-346.
43. Seiden L.S., Sabol K.E. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res. Monogr. 163:1996;251-276.
44. Strassman R.J., Qualls C.R., Uhlenhuth E.H., Kellner R.K. Dose response study of N,N-dimethyltryptamine in humans. Arch. Gen. Psychiat. 51:1994;98-108.
45. Strote J., Lee J.E., Wechsler H. Increasing MDMA use among college students: results of a national survey. J. Adolescent Health. 30:2002;64-72.
46. Tancer M.E., Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 65:2001;97-101.
47. Turner J.J., Parrott A.C. Is MDMA a human neurotoxin?: Diverse views from the discussants. Neuropsychobiology. 42:2000;42-48.
48. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M., Pennings E.J., de Bruin D., Van de Wijngaart G., Van Gerven J.M., Cohen A.F. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology. 153:2001;196-202.
49. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology. 19:1998;241-251.
50. White S.R., Obradovic T., Imel K.M., Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 49:1996;455-479.
51. Zakzanis K.K., Young D.A. Executive function in abstinent MDMA ('ecstasy') users. Med. Sci. Monit. 7:2001;1292-1298.